There’s a new neuroscience company on the Nasdaq. And they’re aiming to change the future of brain health through artificial intelligence.
What’s happening:
- Firefly Neuroscience (NASDAQ: AIFF) has raised an additional $3.5M USD in funding and officially begun trading on the Nasdaq
Why it matters:
- Neuroscience and neurotech companies have been on the rise of late, notably with Elon Musk’s Neuralink completing the first ever chip implant into a human brain and Tether making a significant venture capital investment into Blackrock Neurotech
- Alto Neuroscience (NYSE: ANRO) also previously debuted on the New York Stock Exchange after successfully raising more than $100M USD in their IPO
By the numbers:
- $60M USD of venture capital funding has gone into developing Firefly’s technology platform since inception
- Firefly has successfully completed 77,000 brain scans on 17,000 individual patients
Going deeper:
- Firefly’s artificial intelligence technology platform Brain Network Analytics was previously cleared by the FDA and provides unparalleled insight into brain imaging which can enable more precise diagnoses and potential treatment options for individuals dealing with dementia and mental health conditions
